We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CTVA:NYSECorteva, Inc. Analysis

Data as of 2026-06-01 - not real-time

$78.28

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Corteva is trading at $78.28, just above the calculated support of $78.13 and below its 20‑day ($80.90) and 50‑day ($81.26) moving averages, suggesting limited upside in the immediate term. The bearish MACD histogram and a decreasing volume trend reinforce a neutral‑to‑slightly bearish short‑term bias, while the RSI of 41 indicates the stock is not yet oversold. On the valuation side, the DCF‑derived fair value of $78.96 places the market price within a modest discount, translating to an upside of roughly 15% when measured against the analyst median target of $90.
Fundamentally, CTVA delivers solid top‑line growth of 11% YoY, robust gross (48.6%) and operating (23.7%) margins, and a low debt‑to‑equity ratio of 13.6%, supporting a sustainable dividend yield of 0.92% with a 38% payout ratio. The forward PE of 19.1 contrasts sharply with the trailing PE of 42.3, indicating earnings acceleration, while the low beta (~0.3) and a high 30‑day volatility of 24% suggest limited market correlation but notable price swings. Analyst consensus remains a “Buy” with a mean target near $90, aligning with the upside potential from both DCF and consensus estimates.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering just above technical support
  • Bearish MACD and decreasing volume
  • RSI indicating limited momentum

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth of 11% and improving forward earnings
  • Analyst consensus target around $90 (+15% upside)
  • Sustainable dividend with comfortable payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong margin profile and low leverage
  • Secular demand for seeds and crop protection solutions
  • Undervalued relative to DCF fair value and favorable sector dynamics

Key Metrics & Analysis

Financial Health

Revenue Growth11.00%
Profit Margin6.50%
P/E Ratio42.3
ROE5.14%
ROA4.33%
Debt/Equity13.64
P/B Ratio2.2
Op. Cash Flow$2.6B
Free Cash Flow$2.6B

Technical Analysis

TrendNeutral
RSI41.3
Support$78.13
Resistance$84.32
MA 20$80.90
MA 50$81.26
MA 200$72.53
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14

Valuation

Fair Value$78.96
Target Price$89.90
Upside/Downside14.85%
GradeUndervalued
TypeGrowth
Dividend Yield0.92%

Risk Assessment

Beta0.29
Volatility24.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.